FDLI's Introduction to Drug Law & Regulation
Event | 02.21.08 - 02.22.08, 12:00 AM UTC - 12:00 AM UTC
The Food and Drug Law Institute is committed to providing high quality education and a neutral forum for the generation of ideas and discussion of law and public policy for its legal, policy and regulatory communities.
Teresa Rea is speaking on Hatch-Waxman Issues - The Abbreviated NDA, 505(b)(2) applications and patent and other exclusivity issues. She is also leading a breakout section on Brand vs. Generic Issues: The Strategic Battle for the marketplace.
For more information, please visit these areas: Intellectual Property Litigation, Intellectual Property
Insights
Event | 02.20.25
Has the Buss Stopped? Recoupment Today
Has the Buss Stopped? Recoupment Today: In 1997, the California Supreme Court decided Buss v. Superior Court. In Buss, the court concluded that a liability insurer that defended a mixed action could seek reimbursement from the insured for the defense costs associated with the claims that were not even potentially covered. Since then, numerous courts have held that insurers are entitled to recoup their defense costs associated with uncovered claims or causes of action. On the other hand, a significant number of courts have rejected insurers’ right to recoupment, at least in the absence of a policy provision granting the insurer that right. Some commentators have even suggested that the current judicial trend might be away from permitting insurers to recoup their defense costs. Is that correct? Has the Buss stopped? This panel of coverage experts will analyze insurers’ claimed right to recoupment today, and offer their perspectives on what the law on recoupment should perhaps be and might be in the future.
Event | 12.05.24
Event | 12.05.24
Event | 12.04.24
Inside the Arbitrators’ Chambers: Best Practices of Arbitrators